CN101010086B - 作为免疫和自身免疫调节剂的神经酰胺衍生物 - Google Patents

作为免疫和自身免疫调节剂的神经酰胺衍生物 Download PDF

Info

Publication number
CN101010086B
CN101010086B CN2005800289881A CN200580028988A CN101010086B CN 101010086 B CN101010086 B CN 101010086B CN 2005800289881 A CN2005800289881 A CN 2005800289881A CN 200580028988 A CN200580028988 A CN 200580028988A CN 101010086 B CN101010086 B CN 101010086B
Authority
CN
China
Prior art keywords
cell
galactosylceramide
purposes
mammal
people
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800289881A
Other languages
English (en)
Chinese (zh)
Other versions
CN101010086A (zh
Inventor
S·A·波尔切利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kom Contact Ltd
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of CN101010086A publication Critical patent/CN101010086A/zh
Application granted granted Critical
Publication of CN101010086B publication Critical patent/CN101010086B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
CN2005800289881A 2004-08-27 2005-08-26 作为免疫和自身免疫调节剂的神经酰胺衍生物 Expired - Fee Related CN101010086B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60536204P 2004-08-27 2004-08-27
US60/605,362 2004-08-27
PCT/US2005/030330 WO2006026389A2 (en) 2004-08-27 2005-08-26 Ceramide derivatives as modulators of immunity and autoimmunity

Publications (2)

Publication Number Publication Date
CN101010086A CN101010086A (zh) 2007-08-01
CN101010086B true CN101010086B (zh) 2013-05-29

Family

ID=36000590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800289881A Expired - Fee Related CN101010086B (zh) 2004-08-27 2005-08-26 作为免疫和自身免疫调节剂的神经酰胺衍生物

Country Status (10)

Country Link
US (1) US7772380B2 (https=)
EP (1) EP1784196B1 (https=)
JP (3) JP5226311B2 (https=)
KR (2) KR20120116511A (https=)
CN (1) CN101010086B (https=)
AU (1) AU2005280163B2 (https=)
CA (1) CA2577009C (https=)
IL (1) IL181054A (https=)
NZ (1) NZ553320A (https=)
WO (1) WO2006026389A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
EP1784196B1 (en) * 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JPWO2007043630A1 (ja) * 2005-10-06 2009-04-16 独立行政法人理化学研究所 上気道粘膜下に投与されるｎｋｔ細胞刺激剤
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
DK2056842T3 (da) 2006-04-07 2013-01-14 Univ Chicago Modificeret galactosylceramid til behandling af cancerøse sygdomme
EP2040541B1 (en) * 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
CA2663954A1 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Curcumin analogs, diagnostic methods and genetic markers for diagnosing and treating alzheimer's disease
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
US7959907B2 (en) 2007-02-21 2011-06-14 Vib Vzw Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide
JP5331100B2 (ja) 2007-04-25 2013-10-30 イミュアールエックス・インコーポレーテッド Ｎｋｔアクチベータ、ｃｄ４０アゴニスト、及び任意選択的に抗原を含んでなるアジュバント組合せと、細胞性免疫において相乗的な増強を誘導するためのその使用
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
ES2574825T3 (es) 2007-10-12 2016-06-22 Luigi Panza Análogos de glicolípidos útiles como inmunoadyuvantes
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
ES2798257T3 (es) 2008-09-08 2020-12-10 Childrens Medical Center Administración mucosa de moléculas, proteínas o partículas terapéuticas acopladas a lípidos de ceramida
EP2336144B1 (en) * 2008-09-11 2015-01-21 Riken Esterified alpha-galactosylceramide
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
CN102325875B (zh) * 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
KR20110045545A (ko) * 2009-10-27 2011-05-04 서울대학교산학협력단 신규 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 면역보조용 약학적 조성물
WO2011112889A2 (en) * 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
WO2013007792A1 (en) * 2011-07-14 2013-01-17 Thurgauische Stiftung Für Wissenschaft Und Forschung Novel th2 polarizing compounds
JP2015502340A (ja) * 2011-10-27 2015-01-22 エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｉＮＫＴに対するヒト化抗体
CA2857226A1 (en) * 2011-11-28 2013-06-06 Uti Limited Partnership Prophylactic compositions for management of microbial infections in patients with brain injury
EP2811831B1 (en) * 2012-02-07 2018-04-11 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
KR101969814B1 (ko) * 2012-02-24 2019-04-18 주식회사 진영바이오 글리코실 세라마이드 화합물 및 그 제조방법
TWI633112B (zh) 2012-03-19 2018-08-21 馬克斯普朗克科學發展組織 醣類－醣脂類結合性疫苗
EP2842961B1 (en) * 2012-04-26 2016-12-14 Riken New carbamate glycolipid and use thereof
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
IN2015KN00492A (https=) * 2012-07-26 2015-07-17 Callaghan Innovation Res Ltd
WO2014053482A1 (en) 2012-10-03 2014-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
WO2014088432A1 (en) * 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AU2014214770B2 (en) * 2013-02-08 2018-09-06 Albert Einstein College Of Medicine Inc. Modified glycolipids and methods of making and using the same
TWI773147B (zh) * 2013-03-15 2022-08-01 美商珀金埃爾默健康科技公司 關於用於溶酶體儲積症之測試的化合物及方法
JP6486368B2 (ja) * 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
CN105461681A (zh) * 2014-09-05 2016-04-06 中国科学院生态环境研究中心 具有抗肿瘤活性的krn7000类似物及合成方法
TWI745275B (zh) * 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
KR101589633B1 (ko) * 2014-09-18 2016-02-01 한국과학기술연구원 당세라마이드 유도체 및 이의 제조방법
CN104497065B (zh) * 2014-11-24 2017-10-24 浙江大学 α‑半乳糖神经酰胺新异构体及其用途
CN104497064B (zh) * 2014-11-24 2017-10-24 浙江大学 α‑半乳糖神经酰胺新异构体及其合成方法
CN105384785B (zh) * 2015-11-24 2018-06-19 中国人民解放军第二军医大学 含有半乳糖类脂肪酸衍生物的制备方法及其在医药领域的应用
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
WO2017207040A1 (en) 2016-06-01 2017-12-07 Vib Vzw ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
EP3700549A4 (en) 2017-10-27 2021-08-18 Children's Medical Center Corporation LIPIDS BASED ON SHORT CHAIN CERAMIDES AND THEIR USES
AU2019252912A1 (en) 2018-04-12 2020-10-22 The Children's Medical Center Corporation Ceramide-like lipid-based delivery vehicles and uses thereof
CN109701009A (zh) * 2019-01-03 2019-05-03 华中师范大学 疫苗制剂及其应用
KR102146226B1 (ko) * 2019-03-07 2020-08-20 경희대학교 산학협력단 피토세라마이드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 신경계 자가면역질환의 예방 또는 치료용 조성물
JP7714237B2 (ja) * 2020-11-12 2025-07-29 国立研究開発法人理化学研究所 擬似糖脂質誘導体並びにその合成中間体、製造方法及び用途
EP4301374A4 (en) * 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2023096715A2 (en) * 2021-10-22 2023-06-01 President And Fellows Of Harvard College Immunomodulatory glycosphingolipids and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US6747010B2 (en) * 1997-04-10 2004-06-08 Kirin Beer Kabushiki Kaisha NKT cell-activating agents containing α-glycosylceramides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5853737A (en) 1992-12-10 1998-12-29 Brigham And Women's Hospital Method for inducing a CD1-restricted immune response
US5679347A (en) 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
JP2004131481A (ja) * 1997-04-10 2004-04-30 Kirin Brewery Co Ltd α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
AU2087799A (en) 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1437358B1 (en) * 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003277021A1 (en) * 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
ES2676345T3 (es) * 2003-02-14 2018-07-18 Japan As Represented By President Of National Center Of Neurology And Psychiatry Ministry Of Health Derivados del glicolípido, proceso para su producción, intermedios para la síntesis del mismo, y proceso para la producción de los intermedios
EP1784196B1 (en) * 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US6747010B2 (en) * 1997-04-10 2004-06-08 Kirin Beer Kabushiki Kaisha NKT cell-activating agents containing α-glycosylceramides

Also Published As

Publication number Publication date
US20060052316A1 (en) 2006-03-09
CA2577009A1 (en) 2006-03-09
IL181054A (en) 2013-10-31
JP2015007125A (ja) 2015-01-15
KR101377116B1 (ko) 2014-03-24
AU2005280163A1 (en) 2006-03-09
JP2012211182A (ja) 2012-11-01
KR20120116511A (ko) 2012-10-22
WO2006026389A2 (en) 2006-03-09
CA2577009C (en) 2017-05-02
WO2006026389A3 (en) 2006-05-26
JP2008511634A (ja) 2008-04-17
IL181054A0 (en) 2007-07-04
KR20070023825A (ko) 2007-02-28
EP1784196B1 (en) 2016-12-21
CN101010086A (zh) 2007-08-01
JP5226311B2 (ja) 2013-07-03
JP5870327B2 (ja) 2016-02-24
US7772380B2 (en) 2010-08-10
EP1784196A4 (en) 2012-05-30
EP1784196A2 (en) 2007-05-16
AU2005280163B2 (en) 2011-11-24
NZ553320A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
CN101010086B (zh) 作为免疫和自身免疫调节剂的神经酰胺衍生物
US8022043B2 (en) Ceramide derivatives as modulators of immunity and autoimmunity
Wilson et al. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity
Kaer α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles
Wang et al. Glycoengineering of natural killer cells with CD22 ligands for enhanced anticancer immunotherapy
Brigl et al. CD1: antigen presentation and T cell function
Hong et al. Immune privilege: keeping an eye on natural killer T cells
Kronenberg Toward an understanding of NKT cell biology: progress and paradoxes
Mallevaey et al. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni
Novak et al. Mechanism of regulation of autoimmunity by iNKT cells
Sharif et al. Regulation of autoimmune disease by natural killer T cells
Lalazar et al. Glycolipids as immune modulatory tools
Hung et al. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses
Parekh et al. iNKT-cell responses to glycolipids
Miyake et al. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases
Favreau et al. Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
Romanò et al. Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide
Major et al. The role of invariant natural killer T cells in lupus and atherogenesis
Oh et al. Role of type II NKT cells in the suppression of graft-versus-host disease
EP1605039B1 (en) Dendritic cell presenting alpha-glycosylceramide derivative and a ntigen and usable in suppressing immune response
Miyake et al. Potential of targeting natural killer T cells for the treatment of autoimmune diseases
KR20250121023A (ko) 강글리오사이드 NGcGM3의 합성 변형체 및 암 치료를 위한 그것의 용도
Melo et al. Advance Access Publication Date: 6 May 2018
Gober et al. Gennaro De Libero, Abdijapar Shamshiev, Alena Donda, Vania Manolova
Smith et al. The Zincali: op. 36, no. 4: for three-part chorus of women's voices/David Stanley Smith;[words by] George Eliot from The Spanish gypsy.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: American New York

Patentee after: ALBERT EINSTEIN COLLEGE OF MEDICINE, Inc.

Address before: American New York

Patentee before: Kom contact Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180705

Address after: American New York

Patentee after: Kom contact Ltd.

Address before: American New York

Patentee before: Albert Einstein College of Medicine of Yeshiva University

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130529